Sellas’ cancer vaccine extends survival in blood cancer trial, company says
The vaccine, called galinpepimut-S or GPS, was tested in patients with acute myeloid leukaemia, a fast-growing cancer of the blood and bone marrow
Sellas Life Sciences announced on November 17, 2026 that its experimental cancer vaccine, galinpepimut-S or GPS, extended the survival of patients with acute myeloid leukemia in a late-stage clinical trial. The vaccine, which targets a fast-growing form of blood cancer, resulted in median survival of 24 months for patients who received it, compared to 14.7 months for those who received standard treatment.
Sellas plans to request approval from the U.S. Food and Drug Administration for the vaccine. The company's shares were halted during premarket trading.
Written by urgent.news from The Hindu Health's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.